A treatment recommender clinical decision support system for personalized medicine: method development and proof-of-concept for drug resistant tuberculosis

• Published in: BMC medical informatics and decision making Vol. 22; no. 1; p. 56
• Main Authors: Verboven, Lennert, Calders, Toon, Callens, Steven, Black, John, Maartens, Gary, Dooley, Kelly E, Potgieter, Samantha, Warren, Robin M, Laukens, Kris, Van Rie, Annelies
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.03.2022; BioMed Central; BMC
• Subjects: Clinical decision support system; Decision support systems; Decision Support Systems, Clinical; Drug therapy; Humans; Knowledge Bases; Machine Learning; Precision Medicine; Treatment individualisation; Tuberculosis; Tuberculosis, Multidrug-Resistant - drug therapy; Belgium; Clinical decision support system; Treatment individualisation; Machine learning
• ISSN: 1472-6947; 1472-6947
• DOI: 10.1186/s12911-022-01790-0

Personalized medicine tailors care based on the patient's or pathogen's genotypic and phenotypic characteristics. An automated Clinical Decision Support System (CDSS) could help translate the genotypic and phenotypic characteristics into optimal treatment and thus facilitate implementation of individualized treatment by less experienced physicians. We developed a hybrid knowledge- and data-driven treatment recommender CDSS. Stakeholders and experts first define the knowledge base by identifying and quantifying drug and regimen features for the prototype model input. In an iterative manner, feedback from experts is harvested to generate model training datasets, machine learning methods are applied to identify complex relations and patterns in the data, and model performance is assessed by estimating the precision at one, mean reciprocal rank and mean average precision. Once the model performance no longer iteratively increases, a validation dataset is used to assess model overfitting. We applied the novel methodology to develop a treatment recommender CDSS for individualized treatment of drug resistant tuberculosis as a proof of concept. Using input from stakeholders and three rounds of expert feedback on a dataset of 355 patients with 129 unique drug resistance profiles, the model had a 95% precision at 1 indicating that the highest ranked treatment regimen was considered appropriate by the experts in 95% of cases. Use of a validation data set however suggested substantial model overfitting, with a reduction in precision at 1 to 78%. Our novel and flexible hybrid knowledge- and data-driven treatment recommender CDSS is a first step towards the automation of individualized treatment for personalized medicine. Further research should assess its value in fields other than drug resistant tuberculosis, develop solid statistical approaches to assess model performance, and evaluate their accuracy in real-life clinical settings.